Nationwide Cohort to Estimate Burden of Respiratory Viruses and Immunologic Response (Blood Donor Cohort)
Closed Posted
- Opportunity number
- RFA-IP-24-046
- Agency
-
Centers for Disease Control and Prevention
Department of Health and Human Services
- Applications due
- Award size
- $3,000,000 to $4,500,000
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- County Governments
- Independent School Districts
- State Governments
- Tribal Organizations (Not Federally Recognized)
- City/Township Governments
- 501(c)(3) Nonprofits
- Special District Governments
- Tribal Governments (Federally Recognized)
- For Profit Organizations
- Non-501(c)(3) Nonprofits
- Higher Education Inst. (Public)
- Higher Education Inst. (Private)
- Public or Indian Housing Auth.
Opportunity details come from Grants.gov. Updated .
About this opportunity
This grant opportunity from the Centers for Disease Control and Prevention requests applicants to establish and sustain a national longitudinal cohort of at least 20,000 blood donors providing quarterly samples and surveys to monitor antibodies for SARS-CoV-2, respiratory syncytial virus, influenza, and other respiratory viruses. Successful applicants must perform antibody testing, manage survey and sample data, and disseminate findings to inform public health. Applicants will be evaluated based on their ability to establish the cohort with over 2,000 participants from each of the nine HHS regions. The application due date is February 16, 2024.
The total estimated funding available over the five-year project period is $26.5 million. The single award will fund work to be performed nationwide, with the successful applicant expected to recruit cohort participants from each of the nine Department of Health and Human Services regions.
Synopsis
This project would establish and sustain a national longitudinal cohort of repeat blood donors with the purpose of monitoring changes in antibody titers against common or novel respiratory viruses; surveying the donors to assess for risk factors for infection, vaccination status, respiratory symptoms, and severe illness; and establishing a repository for further analysis as new assays to measure the immune response to respiratory virus infections are developed.During the COVID-19 pandemic, CDC used a contract mechanism to fund national serosurveillance studies, which used regular antibody assessments and surveys to monitor the burden of infection, risk factors for infection, and explore the duration and extend of immunity by population throughout the US (2020-2022). By 2022, algorithms for using quantitative antibody titers to detect reinfection were established and tested, creating novel systems for monitoring burden even in the setting of high overall seroprevalence.Adapting these tools to the current context, this research cooperative agreement would establish a large-scale longitudinal cohort (>50,000 persons) of repeat blood donors with the purpose of: 1) estimating the national burden of incident SARS-CoV-2 infection, and further adapting the approach to other respiratory viruses as technology allows including Respiratory Syncytial Virus, Influenza, Human Metapneumovirus, EVD-68, and others; 2) determining antibody thresholds for protection across multiple respiratory viruses; 3) assessing state- or region-specific population-level immunity to/risk for infection through tracking median antibody titers within various populations; and 4) monitoring waning immunity and changes in immune capabilities in the context of ongoing viral evolution.
Files
| File | Type | Posted |
|---|---|---|
| Foa_Content_of_RFA-IP-24-046 Final.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity